Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe mitochondria to unlock heart failure secrets

NCT ID NCT05770349

Knowledge-focused Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at tiny structures inside heart cells called mitochondria in people with heart failure and clogged arteries. Researchers will take small heart tissue samples during bypass surgery and compare them with blood tests. They want to see if damaged mitochondria are linked to worse outcomes like hospital stays or heart-related death. The goal is to better understand heart failure, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict heart failure progression and tailor treatments based on mitochondrial health.
What could go wrong
This is a small, early observational study, so findings may not apply to all heart failure patients. It aims to understand, not treat, the condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

45-60 patients will be included in the study (15-20 people each - in 2023, 2024 and 2025) who meet the stated inclusion and exclusion criteria. The signing of the informed consent will be carried out before the start of any research procedures, the patient will be explained in detail the protocol of the study and the scope of the diagnostic procedures carried out

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The presence of HFrEF or HFmrEF (EF of LV \<50%) 2. Obstructive multivessel coronary atherosclerosis as an indication for cardiac surgical correction of coronary blood flow (coronary bypass surgery) 3. Signed informed consent to participate in the study, separate consents for biomaterial sampling and genetic research Exclusion Criteria: 1. Refusal of revascularization or participation in the study 2. Additional cardiac surgery other than coronary bypass surgery (valves, aneurysm) 3. Oncological diseases in the active stage; 4. The presence of implanted devices (EX, AICD, CT); 5. Severe renal dysfunction (GFR \<30 ml/min/1.73 m2); 6. Infiltrative heart diseases (sarcoidosis, amyloidosis, accumulation diseases); 7. Autoimmune diseases; 8. Acute infectious and exacerbations of chronic somatic diseases 9. Type 1 or type 2 diabetes mellitus 10. Contraindications to myocardial scintigraphy, cardiopulmonary stress test 11. Impossibility of prescribing optimal drug therapy after cardiac surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tomsk National Research Medical Center, Russian Academy of Sciences

    RECRUITING

    Tomsk, 634050, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.